The better understanding of antitumour immune responses has prompted the development
of immune checkpoint inhibitors (ICIs). Two phase III trials comparing nivolumab vs
docetaxel in patients previously treated with advanced non–small-cell lung cancer
(NSCLC) demonstrated an improved overall survival with the anti–PD-1 drug [
[1]
]. ICI also showed a better safety profile, with about 10% of grade III-IV adverse
events versus 55% for docetaxel [
[1]
]. As anti–PD-1 drugs enhance patient's immune system to fight cancer, they are associated
with immune-related adverse effects (irAEs). irAEs are pleiotropic and can theoretically
damage any tissue or organ of the human body. They mainly include rash, diarrhoea,
colitis, hepatitis, pneumonitis and thyroid dysfunction.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057).J Clin Oncol. 2017; 35: 3924-3933https://doi.org/10.1200/JCO.2017.74.3062
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working Group.J Immunother Cancer. 2017; 5: 95https://doi.org/10.1186/s40425-017-0300-z
- Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.Drug Des Dev Ther. 2018 Jun 8; 12: 1645-1657https://doi.org/10.2147/DDDT.S167077
- Hematologic complications of immune checkpoint inhibitors.Oncol. 2019; 24: 584-588https://doi.org/10.1634/theoncologist.2018-0574
- Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.JAMA Oncol. 2018; 4: 1721-1728https://doi.org/10.1001/jamaoncol.2018.3923
- VigiBase, the WHO global ICSR database system: basic facts.Drug Inf J. 2008; 42: 409-419https://doi.org/10.1177/009286150804200501
Article info
Publication history
Published online: March 11, 2020
Accepted:
February 9,
2020
Received:
December 16,
2019
Identification
Copyright
© 2020 Elsevier Ltd. All rights reserved.
